References
1. Varga J, Trojanowska M, Kuwana M. Pathogenesis of systemic sclerosis:
recent insights of molecular and cellular mechanisms and therapeutic
opportunities. J Scleroderma Relat Disord 2017; 2:137–52.
2. Matsushita T, Hasegawa M, Yanaba K, et al. Elevated serum BAFF levels
in patients with systemic sclerosis: enhanced BAFF signaling in systemic
sclerosis B lymphocytes. Arthritis Rheum 2006; 54:192-201.
3. Basile U, Gulli F, Gragnani L, Napodano C, Pocino K, Rapaccini GL,
Mussap M, Zignego AL. Free light chains: Eclectic multipurpose
biomarker. J Immunol Methods. 2017; 451:11-19.
4. Gulli F, Napodano C, Marino M, Ciasca G, Pocino K, Basile V,
Visentini M, Stefanile A, Todi L, De Spirito M, Rapaccini GL, Basile U.
Serum immunoglobulin free light chain levels in systemic autoimmune
rheumatic diseases. Clin Exp Immunol 2020; 2:163-171.
5. Napodano C, Pocino K, Rigante D, Stefanile A, Gulli F, Marino M,
Basile V, Rapaccini GL, Basile U. Free light chains and autoimmunity.
Autoimmun Rev 2019; 5:484-492.
6. Bosello S, Basile U, De Lorenzis E, Gulli F, Canestrari G, Napodano
C, Parisi F, Pocino K, Di Mario C, Tolusso B, Ferraccioli G, Gremese E.
Free light chains of immunoglobulins in patients with systemic
sclerosis: correlations with lung involvement and inflammatory milieu. J
Clin Pathol 2018; 7:620-625.
7. Halpert G, Shoenfeld Y. SARS-CoV-2, the autoimmune virus.
Autoimmun Rev 2020; 12:102695.
8. Napodano C, Pocino K, Stefanile A, Marino M, Miele L, Gulli F, Basile
V, Pandolfi F, Gasbarrini A, Rapaccini GL, Basile U. COVID-19 and
hepatic involvement: The liver as a main actor of the pandemic novel.
Scand J Immunol 2020; 15:e12977
9. Gupta L, Kharbanda R, Agarwal V, Misra DP, Agarwal V. Patient
Perspectives on the Effect of the SARS-CoV-2 Pandemic on Patients With
Systemic Sclerosis: An International Patient Survey. J Clin Rheumatol
2021; 1:31-33.
10. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall
A, A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE,
Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE,
Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD,
Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk
MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci
S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S,
Silver RM, Simms RW, Varga J, Pope JE. 2013 Classification criteria for
systemic sclerosis: an American college of rheumatology/European league
against rheumatism collaborative initiative. Ann Rheum Dis 2013;
72:1747-55.
11. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA,
Rowell N, Wollheim F. Scleroderma (systemic sclerosis): classification,
subsets and pathogenesis. J Rheumatol 1988; 15:202-05.
12. Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C. Nailfold
capillaroscopy is useful for the diagnosis and follow-up of autoimmune
rheumatic diseases. A future tool for the analysis of microvascular
heart involvement? Rheumatology 2006; 45:43-46.
13. Valentini G, Iudici M, Walker UA, Jaeger VK, Baron M, Carreira P,
Czirják L, Denton CP, Distler O, Hachulla E, Herrick AL, Kowal-Bielecka
O, Pope J, Müller-Ladner U, Riemekasten G, Avouac J, Frerix M, Jordan S,
Minier T, Siegert E , Ong VH, Vettori S, Allanore Y. The European
Scleroderma Trials and Research group (EUSTAR) task force for the
development of revised activity criteria for systemic sclerosis:
derivation and validation of a preliminarily revised EUSTAR activity
index. Ann Rheum Dis 2017; 76:270-76.
14. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesso A, Bacon PA,
Harris CA, Jablonska S, Jayson MI, Jimenez SA, Krieg T, Leroy EC,
Maddison PJ, Russell ML, Schachter RK, Wollheim FA, Zacharaie H. A
disease severity scale for systemic sclerosis: development and testing.
J Rheumatol 1999; 26:2159-67.
15. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R,
et al. Inter and intraobserver variability of total skin thickness score
(modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;
22:1281-85.
16. Gigante A, Rosato E, Massa R, Rossi C, Barbano B, Cianci R, Molinaro
I, Amoroso A, Salsano F. Evaluation of Chronic Kidney Disease
Epidemiology Collaboration equation to estimate glomerular filtration
rate in scleroderma patients. Rheumatology (Oxford). 2012; 8:1426-31.
17. Bramlage CP, Froelich B, Wallbach M, Minguet J, Grupp C, Deutsch C,
Bramlage P, Koziolek M, Müller GA. The significance and predictive value
of free light chains in the urine of patients with chronic inflammatory
rheumatic disease. Clin Rheumatol 2016; 12:2939-2946.
18. Aggarwal R, Sequeira W, Kokebie R, Mikolaitis RA, Fogg L, Finnegan
A, Plaas A, Block JA, Jolly M. Serum free light chains as biomarkers for
systemic lupus erythematosus disease activity. Arthritis Care Res
(Hoboken) 201; 6:891-8.
19. Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B,
Mariette X. Markers of B-lymphocyte activation are elevated in patients
with early rheumatoid arthritis and correlated with disease activity in
the ESPOIR cohort. Arthritis Res Ther 2009; 4:R114.
20. Lanteri A, Sobanski V, Langlois C, Lefèvre G, Hauspie C, Sanges S,
Lambert M, Morell-Dubois S, Hatron PY, Hachulla E, Launay D, Dubucquoi
S. Serum free light chains of immunoglobulins as biomarkers for systemic
sclerosis characteristics, activity, and severity. Autoimmun Rev 2014;
9:974-80.
20. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F,
De Pità O, Puddu P, Paganelli R, Russo G. Cytokine and chemokine levels
in systemic sclerosis: relationship with cutaneous and internal organ
involvement. Clin Exp Immunol 2004; 3:540-6.
21. Bartoccioni E, Scuderi F, Marino M, Provenzano C. IL-6, monocyte
infiltration and parenchymal cells. Trends Immunol 2003; 6:299-300;
22. Marino M, Scuderi F, Provenzano C, Scheller J, Rose-John S,
Bartoccioni E. IL-6 regulates MCP-1, ICAM-1 and IL-6 expression in human
myoblasts. J Neuroimmunol 2008; 1-2:41-8.
23. Marino M, Scuderi F, Ponte E, Maiuri MT, De Cristofaro R, Provenzano
C, Rose-John S, Cittadini A, Bartoccioni E. Novel path to IL-6
trans-signaling through thrombin-induced soluble IL-6 receptor release
by platelets. J Biol Regul Homeost Agents 2013; 3:841-52.
24. Sippl N, Faustini F, Rönnelid J, Turcinov S, Chemin K, Gunnarsson I,
Malmström V. Arthritis in systemic lupus erythematosus is characterized
by local IL-17A and IL-6 expression in synovial fluid. Clin Exp Immunol
2021.
25. Matsushita T, Hasegawa M, Yanaba K, Kodera M, Takehara K, Sato S.
Elevated serum BAFF levels in patients with systemic sclerosis: enhanced
BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum
2006; 1:192-201.
26. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Therneau TM, Colby
CL, Clark RJ, Mead GP, Kumar S, Melton LJ 3rd, Rajkumar SV. Use of
nonclonal serum immunoglobulin free light chains to predict overall
survival in the general population. Mayo Clin Proc 2012; 6:517-23.
27. Hutchison CA, Harding S, Hewins P. Quantitative assessment of serum
and urinary polyclonal free light chains in patients with chronic kidney
disease. Clin J Am Soc Nephrol 2008; 6:1684-1690.
28. Nakano T, Nagata A, Takahashi H. Ratio of urinary free
immunoglobulin light chain kappa to lambda in the diagnosis of Bence
Jones proteinuria. Clin Chem Lab Med 2004; 4:429–434.
29. Rosato E, Gigante A, Barbano B, Gasperini ML, Cianci R, Muscaritoli
M. Prognostic Factors of Renal Involvement in Systemic Sclerosis. Kidney
Blood Press Res 2018; 3:682-689.
30. Shanmugam VK, Steen VD. Renal disease in scleroderma: an update on
evaluation, risk stratification, pathogenesis and management. Curr Opin
Rheumatol 2012; 6:669-76.
31. Livi R, Teghini L, Pignone A, Generini S, Matucci-Cerinic M, Cagnoni
M. Renal functional reserve is impaired in patients with systemic
sclerosis without clinical signs of kidney involvement. Ann Rheum Dis
2002; 8:682-6.
32. Clements PJ, Lachenbruch PA, Furst DE, Maxwell M, Danovitch G,
Paulus HE. Abnormalities of renal physiology in systemic sclerosis. A
prospective study with 10 year follow up. Arthritis Rheum 1994;
37:67–74.
33. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR,
Cockwell P. Quantitative assessment of serum and urinary polyclonal free
light chains in patients with chronic kidney disease. Clin J Am Soc
Nephrol 2008; 6:1684-90.
34. Basnayake K, Stringer SJ, Hutchison CA, Cockwell P. The biology of
immunoglobulin free light chains and kidney injury. Kidney Int 2011;
79:1289-301.
35. Liu Y. New insights into epithelial-mesenchymal transition in kidney
fibrosis. J AmSoc Nephrol 2010; 21:212-22.
36. Basile U, Marino M, Napodano C, Pocino K, Alboini PE, Gulli F, Evoli
A, Provenzano C, Bartoccioni E. Serological Immunoglobulin-Free Light
Chain Profile in Myasthenia Gravis Patients. J Immunol Res 2018; 2018:
9646209.